Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

A higher throughput and physiologically relevant two-compartmental human ex vivo intestinal tissue system for studying gastrointestinal processes.

Stevens LJ, van Lipzig MMH, Erpelinck SLA, Pronk A, van Gorp J, Wortelboer HM, van de Steeg E.

Eur J Pharm Sci. 2019 Sep 1;137:104989. doi: 10.1016/j.ejps.2019.104989. Epub 2019 Jul 10.

PMID:
31301485
2.

Mechanisms and immunomodulatory properties of pre- and probiotics.

Peters VBM, van de Steeg E, van Bilsen J, Meijerink M.

Benef Microbes. 2019 Apr 19;10(3):225-236. doi: 10.3920/BM2018.0066. Epub 2019 Mar 4. Review.

PMID:
30827150
3.

Proteomics of human liver membrane transporters: a focus on fetuses and newborn infants.

van Groen BD, van de Steeg E, Mooij MG, van Lipzig MMH, de Koning BAE, Verdijk RM, Wortelboer HM, Gaedigk R, Bi C, Leeder JS, van Schaik RHN, van Rosmalen J, Tibboel D, Vaes WH, de Wildt SN.

Eur J Pharm Sci. 2018 Nov 1;124:217-227. doi: 10.1016/j.ejps.2018.08.042. Epub 2018 Aug 30.

4.

An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota.

van de Steeg E, Schuren FHJ, Obach RS, van Woudenbergh C, Walker GS, Heerikhuisen M, Nooijen IHG, Vaes WHJ.

Drug Metab Dispos. 2018 Nov;46(11):1596-1607. doi: 10.1124/dmd.118.081026. Epub 2018 Aug 29.

PMID:
30158249
5.

Corrigendum to 'Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs' [European Journal of Pharmaceutical Sciences 115 (2018) 175-184].

Notenboom S, Weigand KM, Proost JH, van Lipzig MM, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 May 30;117:392-393. doi: 10.1016/j.ejps.2018.04.005. No abstract available.

PMID:
29650218
6.

Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs.

Notenboom S, Weigand KM, Proost JH, van Lipzig MMH, van de Steeg E, van den Broek PHH, Greupink R, Russel FGM, Groothuis GMM.

Eur J Pharm Sci. 2018 Mar 30;115:175-184. doi: 10.1016/j.ejps.2018.01.007. Epub 2018 Jan 5. Erratum in: Eur J Pharm Sci. 2018 May 30;117:392-393.

7.

Comparison of In Vitro Assays in Selecting Radiotracers for In Vivo P-Glycoprotein PET Imaging.

Raaphorst RM, Savolainen H, Cantore M, van de Steeg E, van Waarde A, Colabufo NA, Elsinga PH, Lammertsma AA, Windhorst AD, Luurtsema G.

Pharmaceuticals (Basel). 2017 Sep 20;10(3). pii: E76. doi: 10.3390/ph10030076.

8.

Variability in Mass Spectrometry-based Quantification of Clinically Relevant Drug Transporters and Drug Metabolizing Enzymes.

Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, Oswald S, Norén A, Weiss F, Hammer HS, Joos TO, Poetz O, Achour B, Rostami-Hodjegan A, van de Steeg E, Wortelboer HM, Artursson P.

Mol Pharm. 2017 Sep 5;14(9):3142-3151. doi: 10.1021/acs.molpharmaceut.7b00364. Epub 2017 Aug 16.

9.

Feasibility of SPECT-CT Imaging to Study the Pharmacokinetics of Antisense Oligonucleotides in a Mouse Model of Duchenne Muscular Dystrophy.

van de Steeg E, Läppchen T, Aguilera B, Jansen HT, Muilwijk D, Vermue R, van der Hoorn JW, Donato K, Rossin R, de Visser PC, Vlaming MLH.

Nucleic Acid Ther. 2017 Aug;27(4):221-231. doi: 10.1089/nat.2016.0649. Epub 2017 Apr 18.

PMID:
28418733
10.

Regional Expression Levels of Drug Transporters and Metabolizing Enzymes along the Pig and Human Intestinal Tract and Comparison with Caco-2 Cells.

Vaessen SF, van Lipzig MM, Pieters RH, Krul CA, Wortelboer HM, van de Steeg E.

Drug Metab Dispos. 2017 Apr;45(4):353-360. doi: 10.1124/dmd.116.072231. Epub 2017 Feb 2.

PMID:
28153842
11.

The consequence of regional gradients of P-gp and CYP3A4 for drug-drug interactions by P-gp inhibitors and the P-gp/CYP3A4 interplay in the human intestine ex vivo.

Li M, de Graaf IA, van de Steeg E, de Jager MH, Groothuis GM.

Toxicol In Vitro. 2017 Apr;40:26-33. doi: 10.1016/j.tiv.2016.12.002. Epub 2016 Dec 7.

PMID:
27939799
12.

Proteomic Analysis of the Developmental Trajectory of Human Hepatic Membrane Transporter Proteins in the First Three Months of Life.

Mooij MG, van de Steeg E, van Rosmalen J, Windster JD, de Koning BA, Vaes WH, van Groen BD, Tibboel D, Wortelboer HM, de Wildt SN.

Drug Metab Dispos. 2016 Jul;44(7):1005-13. doi: 10.1124/dmd.115.068577. Epub 2016 Apr 21.

PMID:
27103634
13.

PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.

Vlaming ML, Läppchen T, Jansen HT, Kivits S, van Driel A, van de Steeg E, van der Hoorn JW, Sio CF, Steinbach OC, DeGroot J.

Nucl Med Biol. 2015 Nov;42(11):833-41. doi: 10.1016/j.nucmedbio.2015.07.004. Epub 2015 Jul 15.

PMID:
26264927
14.

Quantifying phenotypic flexibility as the response to a high-fat challenge test in different states of metabolic health.

Kardinaal AF, van Erk MJ, Dutman AE, Stroeve JH, van de Steeg E, Bijlsma S, Kooistra T, van Ommen B, Wopereis S.

FASEB J. 2015 Nov;29(11):4600-13. doi: 10.1096/fj.14-269852. Epub 2015 Jul 21.

PMID:
26198450
15.

Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis.

Sticova E, Lodererova A, van de Steeg E, Frankova S, Kollar M, Lanska V, Kotalova R, Dedic T, Schinkel AH, Jirsa M.

Int J Clin Exp Pathol. 2015 May 1;8(5):5252-62. eCollection 2015.

16.

Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3.

van de Steeg E, Venhorst J, Jansen HT, Nooijen IH, DeGroot J, Wortelboer HM, Vlaming ML.

Eur J Pharm Sci. 2015 Apr 5;70:29-36. doi: 10.1016/j.ejps.2015.01.004. Epub 2015 Jan 17.

PMID:
25603031
17.

Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling.

Bosgra S, van de Steeg E, Vlaming ML, Verhoeckx KC, Huisman MT, Verwei M, Wortelboer HM.

Eur J Pharm Sci. 2014 Dec 18;65:156-66. doi: 10.1016/j.ejps.2014.09.007. Epub 2014 Sep 28.

PMID:
25261337
18.

A new approach to predict human intestinal absorption using porcine intestinal tissue and biorelevant matrices.

Westerhout J, van de Steeg E, Grossouw D, Zeijdner EE, Krul CA, Verwei M, Wortelboer HM.

Eur J Pharm Sci. 2014 Oct 15;63:167-77. doi: 10.1016/j.ejps.2014.07.003. Epub 2014 Jul 18.

PMID:
25046168
19.

Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel.

Iusuf D, Hendrikx JJ, van Esch A, van de Steeg E, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH.

Int J Cancer. 2015 Jan 1;136(1):225-33. doi: 10.1002/ijc.28970. Epub 2014 Jun 3.

20.

Bcrp1;Mdr1a/b;Mrp2 combination knockout mice: altered disposition of the dietary carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) and its genotoxic metabolites.

Vlaming ML, Teunissen SF, van de Steeg E, van Esch A, Wagenaar E, Brunsveld L, de Greef TF, Rosing H, Schellens JH, Beijnen JH, Schinkel AH.

Mol Pharmacol. 2014 Mar;85(3):520-30. doi: 10.1124/mol.113.088823. Epub 2013 Dec 13.

PMID:
24334255
21.

OATP1A/1B transporters affect irinotecan and SN-38 pharmacokinetics and carboxylesterase expression in knockout and humanized transgenic mice.

Iusuf D, Ludwig M, Elbatsh A, van Esch A, van de Steeg E, Wagenaar E, van der Valk M, Lin F, van Tellingen O, Schinkel AH.

Mol Cancer Ther. 2014 Feb;13(2):492-503. doi: 10.1158/1535-7163.MCT-13-0541. Epub 2013 Nov 5.

22.

Combined analysis of pharmacokinetic and efficacy data of preclinical studies with statins markedly improves translation of drug efficacy to human trials.

van de Steeg E, Kleemann R, Jansen HT, van Duyvenvoorde W, Offerman EH, Wortelboer HM, Degroot J.

J Pharmacol Exp Ther. 2013 Dec;347(3):635-44. doi: 10.1124/jpet.113.208595. Epub 2013 Sep 18.

PMID:
24049060
23.

Murine Oatp1a/1b uptake transporters control rosuvastatin systemic exposure without affecting its apparent liver exposure.

Iusuf D, van Esch A, Hobbs M, Taylor M, Kenworthy KE, van de Steeg E, Wagenaar E, Schinkel AH.

Mol Pharmacol. 2013 May;83(5):919-29. doi: 10.1124/mol.112.081927. Epub 2013 Feb 19.

PMID:
23429889
24.

Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.

van de Steeg E, Greupink R, Schreurs M, Nooijen IH, Verhoeckx KC, Hanemaaijer R, Ripken D, Monshouwer M, Vlaming ML, DeGroot J, Verwei M, Russel FG, Huisman MT, Wortelboer HM.

Drug Metab Dispos. 2013 Mar;41(3):592-601. doi: 10.1124/dmd.112.049023. Epub 2012 Dec 17.

PMID:
23248200
25.

Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.

van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2013 Feb 15;19(4):821-32. doi: 10.1158/1078-0432.CCR-12-2080. Epub 2012 Dec 14.

26.

Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification.

Iusuf D, van de Steeg E, Schinkel AH.

Clin Pharmacol Ther. 2012 Nov;92(5):559-62. doi: 10.1038/clpt.2012.143. Epub 2012 Sep 26. No abstract available.

PMID:
23010652
27.

Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.

Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, Schinkel AH.

Mol Pharm. 2012 Sep 4;9(9):2497-504. doi: 10.1021/mp300108c. Epub 2012 Aug 3.

PMID:
22812517
28.

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver.

van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH.

J Clin Invest. 2012 Feb;122(2):519-28. doi: 10.1172/JCI59526. Epub 2012 Jan 9.

29.

Functions of OATP1A and 1B transporters in vivo: insights from mouse models.

Iusuf D, van de Steeg E, Schinkel AH.

Trends Pharmacol Sci. 2012 Feb;33(2):100-8. doi: 10.1016/j.tips.2011.10.005. Epub 2011 Nov 28. Review.

PMID:
22130008
30.

Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate.

Vlaming ML, van Esch A, van de Steeg E, Pala Z, Wagenaar E, van Tellingen O, Schinkel AH.

Drug Metab Dispos. 2011 Aug;39(8):1338-44. doi: 10.1124/dmd.111.038794. Epub 2011 May 12.

PMID:
21566011
31.

High impact of Oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel.

van de Steeg E, van Esch A, Wagenaar E, van der Kruijssen CM, van Tellingen O, Kenworthy KE, Schinkel AH.

Clin Cancer Res. 2011 Jan 15;17(2):294-301. doi: 10.1158/1078-0432.CCR-10-1980. Epub 2010 Nov 19.

32.

Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs.

van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH.

J Clin Invest. 2010 Aug;120(8):2942-52. doi: 10.1172/JCI42168. Epub 2010 Jul 19.

33.

Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.

Oostendorp RL, van de Steeg E, van der Kruijssen CM, Beijnen JH, Kenworthy KE, Schinkel AH, Schellens JH.

Drug Metab Dispos. 2009 Apr;37(4):917-23. doi: 10.1124/dmd.108.024901. Epub 2009 Jan 12.

PMID:
19139163
34.

Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1).

van de Steeg E, van der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH.

Drug Metab Dispos. 2009 Feb;37(2):277-81. doi: 10.1124/dmd.108.024315. Epub 2008 Nov 20.

PMID:
19022939
35.

Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2).

Zimmermann C, van de Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH.

Drug Metab Dispos. 2008 Apr;36(4):631-40. doi: 10.1124/dmd.107.019620. Epub 2008 Jan 7.

PMID:
18180270
36.

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Casas C, Sergeant N, Itier JM, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L.

Am J Pathol. 2004 Oct;165(4):1289-300.

Supplemental Content

Loading ...
Support Center